GPT and hepatocellular carcinoma: The initial trials for ICI in HCC after initial systemic therapy (CHECKMATE 040 with nivolumab and KEYNOTE-224 with pembrolizumab), reported ALT elevations of any grade in up to 15% and grade ≥3 in 4-6% of patients (28, 37).